SAN DIEGO, July 26, 2012 /PRNewswire/ -- ADVENTRX
Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it is
presenting at the 1st Annual Sickle Cell Disease
Therapeutics Conference. The conference is intended to serve as a
forum to raise awareness for sickle cell disease and will include
presentations from leading companies in sickle cell disease and
discussions with experts regarding the latest advancements and
future trends for patients. The conference will be held
September 19, 2012 in the
Cosmopolitan Suite at the Four Seasons Hotel in New York City. Conference sponsors include
Theradex Systems, Inc. and Rodman & Renshaw, LLC.
(Logo:
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)
Six public and private companies developing new treatment
options for patients with sickle cell disease, including ADVENTRX
Pharmaceuticals, Inc., will make presentations. Additionally,
clinical researchers investigating approved agents from leading
pharmaceutical companies, such as Eisai, Astellas and Lilly, also
will present.
Conference attendees will hear from leaders in the sickle cell
disease medical and advocacy communities, including:
- Lanetta B. Jordan, MD, MPH,
MSPH, Associate Professor at the University of
Miami Miller School of Medicine and Chief Medical Officer of
the Sickle Cell Disease Association of America, Inc. (SCDAA)
- Kim Smith-Whitley, MD, Medical
Director of the Sickle Cell Clinical Program, Clinical Director of
the Division of Hematology, and Attending Physician at The
Children's Hospital of Philadelphia
- Denis Soulieres, MD, MSc, FRCPC
Director of the Molecular Biology and Hematology Laboratory,
Oncology & Hematology at the University of
Montreal
- Mary M. Hulihan, MPH, Centers
for Disease Control (CDC), Division of Blood Disorders of the
National Center on Birth Defects and Developmental
Disabilities
Question & answer sessions will be moderated by the
following healthcare analysts:
- Michael Higgins, Life Sciences
Analyst, Brinson Patrick Securities Corporation
- Michael King, Managing Director
and Senior Biotechnology Analyst, Rodman & Renshaw, LLC
- Christian Glennie, Healthcare
Analyst, Edison Investment Research, Ltd.
"We are excited to present at the Sickle Cell Disease
Therapeutics Conference at a time when our product candidate,
ANX-188, is poised to commence its Phase 3 clinical study," stated
Brian M. Culley, Chief Executive
Officer of ADVENTRX. "The disease was identified over one hundred
years ago, but only one FDA-approved drug is available, and none
are available to treat an on-going vaso-occlusive crisis or the
underlying ischemia and infarction that reduce the average life
expectancy to less than 40 years. Awareness leads to
investment, development, and eventually, to new treatments. This
conference is an excellent forum to discuss with investors and
potential licensing partners the latest advancements for patients
suffering with this rare disease."
More information can be found on the conference web site at
www.scdconference.com or on the advertising flyer for the event at
www.scdconference.com/wp-content/uploads/2012/07/SCDTC_InformationPage.pdf.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company
developing proprietary product candidates to treat various diseases
and conditions. The Company's lead product candidate is ANX-188, a
rheologic, anti-thrombotic, anti-inflammatory and cytoprotective
agent that reduces ischemic tissue injury and end-organ damage by
restoring impaired microvascular blood flow, and has potential
application in treating a wide range of diseases and conditions,
such as complications arising from sickle cell disease. More
information can be found on the Company's web site at
www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press
release that are not a description of historical facts are
forward-looking statements that are based on ADVENTRX's current
expectations and assumptions. Such forward-looking statements
include, but are not limited to, statements regarding the timing of
the Phase 3 study of ANX-188 and the potential for the conference
to lead to increased investment in and development of new therapies
for patients with sickle cell disease. Among the factors that could
cause or contribute to material differences between ADVENTRX's
actual results and those indicated from the forward-looking
statements are risks and uncertainties inherent in ADVENTRX's
business, including, but not limited to: the potential for delays
in the commencement of planned clinical studies, including as a
result of difficulties or delays in completing manufacturing
process development activities and manufacturing clinical trial
material or difficulties or delays in obtaining regulatory
agreement on clinical study design or meeting applicable regulatory
requirements for clinical trial material; the risk of suspension or
termination of a clinical study including due to lack of adequate
funding; the risk that planned clinical studies are not successful
and, even if they are successful, that the FDA could determine they
are not sufficient to support an NDA; the potential for ADVENTRX to
delay, reduce or discontinue current and/or planned development
activities, partner its product candidates at inopportune times or
pursue less expensive but higher-risk development paths if it is
unable to raise sufficient additional capital as needed; ADVENTRX's
ability to obtain additional funding on a timely basis or on
acceptable terms, or at all; and other risks and uncertainties more
fully described in ADVENTRX's press releases and periodic filings
with the Securities and Exchange Commission. ADVENTRX's public
filings with the Securities and Exchange Commission are available
at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. ADVENTRX
does not intend to revise or update any forward-looking statement
set forth in this press release to reflect events or circumstances
arising after the date hereof, except as may be required by
law.
SOURCE ADVENTRX Pharmaceuticals, Inc.